Recent Analysts’ Ratings Changes for Regulus Therapeutics (RGLS)

Several brokerages have updated their recommendations and price targets on shares of Regulus Therapeutics (NASDAQ: RGLS) in the last few weeks:

• 4/8/2024 – Regulus Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/31/2024 – Regulus Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/25/2024 – Regulus Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
• 3/23/2024 – Regulus Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/19/2024 – Regulus Therapeutics had its price target lowered by analysts at Canaccord Genuity Group Inc. from $12.00 to $11.00. They now have a “buy” rating on the stock.
• 3/18/2024 – Regulus Therapeutics had its “outperform” rating reaffirmed by analysts at Leerink Partnrs.
• 3/18/2024 – Regulus Therapeutics is now covered by analysts at SVB Leerink LLC. They set an “outperform” rating and a $6.00 price target on the stock.
• 3/18/2024 – Regulus Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
• 3/15/2024 – Regulus Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/13/2024 – Regulus Therapeutics had its price target raised by analysts at Wells Fargo & Company from $2.00 to $3.00. They now have an “equal weight” rating on the stock.
• 3/7/2024 – Regulus Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/28/2024 – Regulus Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/20/2024 – Regulus Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/12/2024 – Regulus Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Regulus Therapeutics Price Performance

Shares of Regulus Therapeutics stock remained flat at $2.78 during trading hours on Friday. 187,682 shares of the stock were exchanged, compared to its average volume of 2,700,859. The stock has a market capitalization of $181.98 million, a P/E ratio of -1.75 and a beta of 1.57. Regulus Therapeutics Inc. has a fifty-two week low of $0.92 and a fifty-two week high of $3.79. The firm has a 50-day moving average price of $2.00 and a two-hundred day moving average price of $1.55.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, hitting the consensus estimate of ($0.40). As a group, research analysts anticipate that Regulus Therapeutics Inc. will post -0.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Regulus Therapeutics

Large investors have recently added to or reduced their stakes in the business. FMR LLC grew its holdings in Regulus Therapeutics by 32.4% during the 3rd quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock worth $4,033,000 after acquiring an additional 716,000 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Regulus Therapeutics by 5.3% during the 3rd quarter. Victory Capital Management Inc. now owns 233,207 shares of the biopharmaceutical company’s stock worth $322,000 after purchasing an additional 11,701 shares during the last quarter. Federated Hermes Inc. acquired a new position in shares of Regulus Therapeutics during the first quarter worth $8,656,000. Vanguard Group Inc. increased its holdings in Regulus Therapeutics by 21.4% in the first quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock valued at $1,096,000 after buying an additional 648,121 shares during the last quarter. Finally, Exome Asset Management LLC acquired a new stake in Regulus Therapeutics in the fourth quarter valued at $228,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.